Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $5.2 million.

  • TScan Therapeutics' Current Deferred Revenue fell 4779.54% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 4779.54%. This contributed to the annual value of $11.7 million for FY2024, which is 1539.9% up from last year.
  • As of Q3 2025, TScan Therapeutics' Current Deferred Revenue stood at $5.2 million, which was down 4779.54% from $7.7 million recorded in Q2 2025.
  • In the past 5 years, TScan Therapeutics' Current Deferred Revenue registered a high of $19.2 million during Q2 2023, and its lowest value of $3.9 million during Q4 2022.
  • For the 5-year period, TScan Therapeutics' Current Deferred Revenue averaged around $10.3 million, with its median value being $10.4 million (2024).
  • As far as peak fluctuations go, TScan Therapeutics' Current Deferred Revenue crashed by 6604.73% in 2022, and later skyrocketed by 16166.75% in 2023.
  • Over the past 5 years, TScan Therapeutics' Current Deferred Revenue (Quarter) stood at $11.4 million in 2021, then crashed by 66.05% to $3.9 million in 2022, then skyrocketed by 161.67% to $10.1 million in 2023, then grew by 15.4% to $11.7 million in 2024, then tumbled by 55.67% to $5.2 million in 2025.
  • Its Current Deferred Revenue was $5.2 million in Q3 2025, compared to $7.7 million in Q2 2025 and $10.3 million in Q1 2025.